{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:56:21Z","timestamp":1766400981857},"reference-count":26,"publisher":"Impact Journals, LLC","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,28]]},"DOI":"10.18632\/oncotarget.9485","type":"journal-article","created":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T08:07:06Z","timestamp":1463731626000},"page":"40085-40094","source":"Crossref","is-referenced-by-count":19,"title":["Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study"],"prefix":"10.18632","volume":"7","author":[{"given":"Elena","family":"Verzoni","sequence":"first","affiliation":[{"name":"Unit of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo De","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRST, IRCCS, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 2, Istituto Toscano Tumori, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[{"name":"Ospedale Santa Chiara, Trento, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Boccardo","sequence":"additional","affiliation":[{"name":"IRCCS AOU San Martino IST and University of Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Uro-Gynecological Oncology, Istituto Nazionale Tumori, Fondazione G. Pascale IRCCS, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Porcu","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio De","family":"Vincenzo","sequence":"additional","affiliation":[{"name":"Istituto Clinico Humanitas, Rozzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[{"name":"Fondazione Poliambulanza, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo Emanuele","family":"Chiuri","sequence":"additional","affiliation":[{"name":"Ospedale Vito Fazzi, Lecce, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Fratino","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori CRO, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Policlinico Universitario Campus Biomedico, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Adamo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, AO Papardo, Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco De","family":"Vivo","sequence":"additional","affiliation":[{"name":"Ospedale San Bortolo, Vicenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Dinota","sequence":"additional","affiliation":[{"name":"Ospedale San Carlo, Potenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Messina","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Ricotta","sequence":"additional","affiliation":[{"name":"Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Caserta","sequence":"additional","affiliation":[{"name":"AO Santa Maria, Terni, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Scavelli","sequence":"additional","affiliation":[{"name":"Ospedale S. Cuore di Ges\u00f9, Gallipoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Susi","sequence":"additional","affiliation":[{"name":"Ospedale Madonna delle Grazie, Matera, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Tartarone","sequence":"additional","affiliation":[{"name":"IRCCS Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Surace","sequence":"additional","affiliation":[{"name":"Ospedale D. Camberlingo, Francavilla Fontana, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mosca","sequence":"additional","affiliation":[{"name":"AOU Maggiore della Carit\u00e0, Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Bruno","sequence":"additional","affiliation":[{"name":"PO San G. Moscati, ASL Taranto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Barni","sequence":"additional","affiliation":[{"name":"AO Treviglio, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Grassi","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,19]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2015.999044","article-title":"Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?","volume":"15","author":"Antonarakis","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","article-title":"Serial blood-based analysis of AR-V7 in men with advanced prostate cancer","volume":"26","author":"Antonarakis","year":"2015","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/annonc\/mdv179","article-title":"Prioritizing precision medicine for prostate cancer","volume":"26","author":"Beltran","year":"2015","journal-title":"Ann Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Beer","year":"2015","journal-title":"Ann Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Goodman","year":"2012","journal-title":"Lancet Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","article-title":"Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer","volume":"61","author":"Scher","year":"2012","journal-title":"Eur Urol"},{"key":"7","first-page":"1","article-title":"\u201cNatural course\u201d of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment","author":"Foss\u00e5","year":"2015","journal-title":"Scand J Urol"},{"key":"8","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Smith","year":"2006","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.urolonc.2010.07.002","article-title":"Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy","volume":"30","author":"Tannock","year":"2012","journal-title":"Urol Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.eururo.2013.08.007","article-title":"Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study","volume":"66","author":"de Wit","year":"2014","journal-title":"Eur Urol"},{"key":"11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00345-014-1375-5","article-title":"Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort","volume":"33","author":"Gr\u00fcllich","year":"2015","journal-title":"World J Urol"},{"key":"12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdv545","article-title":"Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials","volume":"27","author":"Ohlmann","year":"2016","journal-title":"Ann Oncol"},{"key":"13","first-page":"1057","article-title":"Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer","volume":"35","author":"Porfiri","year":"2015","journal-title":"Anticancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Fizazi","year":"2015","journal-title":"Eur J Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/pcan.2013.41","article-title":"Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"17","author":"Scher","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16","first-page":"12520","article-title":"Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment","volume":"14","author":"Santini","year":"2015","journal-title":"Oncotarget"},{"key":"17","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/1078-0432.CCR-14-1961","article-title":"Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate","volume":"21","author":"Ricci","year":"2015","journal-title":"Clin Cancer Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.18632\/oncotarget.2558","article-title":"Early outcome prediction on 18F-fluorocholine PET\/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"5","author":"Matteucci","year":"2014","journal-title":"Oncotarget"},{"key":"19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/annonc\/mdu587","article-title":"Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use","volume":"26","author":"de Bono","year":"2015","journal-title":"Ann Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Kheoh","year":"2015","journal-title":"J Clin Oncol"},{"key":"21","first-page":"33","article-title":"Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): analysis of the COU-AA-301 and IMMC38 trials","author":"Kheoh","year":"2015","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"de Bono","year":"2014","journal-title":"Ann Oncol"},{"key":"23","first-page":"33","article-title":"High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)","author":"Maines","year":"2015","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12885-015-1257-2","article-title":"Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for use programme in France","volume":"15","author":"Laguerre","year":"2015","journal-title":"BMC Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pros.23141","article-title":"Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies","volume":"76","author":"Eisenberger","year":"2016","journal-title":"Prostate"},{"key":"26","volume-title":"Classification and regression trees","author":"Stone","year":"1984"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T08:07:32Z","timestamp":1600589252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,19]]},"references-count":26,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6,28]]}},"alternative-id":["9485","27223078"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9485","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,19]]}}}